LONDON, Dec 10 (Reuters) – Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine therapy, ‍in what it said marked the first big advance in hormonal treatment for the disease in over 20 years.

The Swiss drugmaker said detailed results from the phase III lidERA trial showed at three years, 92.4% of patients in the giredestrant arm were alive ‌and disease-free versus 89.6% in the standard-of-care ‌arm.

The company had last month published only a brief summary of the results, saying the primary goals were met.

“When you talk about a 30% increase in disease-free survival, you’re basically saying 30% of these patients who in standard of care would still have gone on to recur – you’re getting 30% few

See Full Page